PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Atogepant - Migraine (prevention)

PAD Profile : Atogepant - Migraine (prevention)

Keywords :
migraine prevention, migraine prophylaxis, calcitonin gene-related peptide, CGRP
Brand Names Include :
Aquipta

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
07 August 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves atogepant for preventing migraine in line with recommendations made in NICE TA973 Atogepant for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians). Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Associated BNF Codes

04. Central Nervous System
04.07.04. Antimigraine drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More